一种与肺癌相关的生物标志物组合、含其的试剂盒及其用途
By using liquid-phase chip detection of biomarker combinations such as ESO-1, TM4SF1, p53, BMI1, FXR1, EFHD2, BRAF, CAGE antigen, or their autoantibodies, the problem of low sensitivity and specificity in early lung cancer diagnosis has been solved, enabling efficient early lung cancer screening and post-treatment monitoring.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- GUANGZHOU BIO BLUE TECH CO LTD
- Filing Date
- 2022-07-01
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies for early lung cancer diagnosis or prognosis use biomarker combinations or kits with low sensitivity and specificity, making them ineffective for early lung cancer screening and detection in high-risk populations.
A combination of biomarkers, including ESO-1, TM4SF1, p53, BMI1, FXR1 and EFHD2 antigens or their autoantibodies, combined with BRAF and/or CAGE antigens or their autoantibodies, is used to detect lung cancer-related antigen autoantibodies in serum using liquid-phase chip technology, and coupled magnetic beads are used for high-throughput detection.
It improves the sensitivity and specificity of early lung cancer diagnosis, and can more accurately detect lung cancer-related antigens and autoantibodies. It has high throughput, specificity and sensitivity, and is suitable for early lung cancer screening and recurrence monitoring after treatment.
Smart Images
Figure QLYQS_2 
Figure BDA0003726719530000061 
Figure BDA0003726719530000111